A non-interventional study on effectiveness of Eylea in RAP lesions
Research type
Research Study
Full title
A non-interventional study looking at the visual and anatomical outcomes in patients with the retinal angiomatous proliferation (RAP) subtype of wet age-related macular degeneration, treated with intravitreal Aflibercept (Eylea) as part of their routine care
IRAS ID
172260
Contact name
Andrew Browning
Contact email
Sponsor organisation
Nuth
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Retinal angiomatous proliferation(RAP)is a distinct form of wet age-related macular degeneration(AMD).Studies demonstrate that the entity is present in approximately 8-15% of all cases of wet AMD and that most patients develop a similar lesion in their fellow eye within 3 years of the first eye being diagnosed. Until recently, it was thought,that the diagnosis of RAP in a patient with untreated neovascular AMD was linked to a poor visual prognosis,especially when compared with untreated non-RAP wet AMD cases. Until the advent of anti-VEGF treatments, it was widely accepted that there was a general lack of response of RAP lesions to previously available interventions such as focal argon laser, Visudyne PDT or transpupillary thermotherapy.The aim of this study is to collect data retrospectively on the visual and anatomical outcomes of patients undergoing aflibercept treatment for wet AMD who are identified as having the RAP subtype of disease at baseline and who have completed at least 12 months of follow up. We are planning to recruite 40 patients.In order to improve our understanding of the effectiveness of treatment, the patient’s anonymized baseline fluorescein and ICG angiograms and OCT scans will be independently assessed and graded for disease severity by an external NHS angiogram reading centre.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
15/EE/0290
Date of REC Opinion
17 Jul 2015
REC opinion
Favourable Opinion